Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Language
Document Type
Year range
1.
Int J Environ Res Public Health ; 20(3)2023 02 01.
Article in English | MEDLINE | ID: covidwho-2254850

ABSTRACT

BACKGROUND: Pulmonary tuberculosis (TB), a global health problem, is typically caused by the bacterium Mycobacterium tuberculosis. Herpes zoster (HZ) is caused by the reactivation of the varicella-zoster virus (VZV). The reactivation of VZV can be caused by stress. We investigated whether pulmonary TB increases the risk of HZ development. METHODS: This study used data that sampled a population of 2 million people in 2000 from the National Health Insurance Research Database. This cohort study observed Taiwanese patients aged 20-100 years with pulmonary TB from 2000 to 2017 (tracked to 2018). Pulmonary TB was defined as having two or more outpatient diagnoses or at least one admission record. To address potential bias caused by confounding factors, the control cohort and pulmonary TB cohort were matched 1:1 by age, gender, index year, and comorbidities. Patients with HZ before the index date were excluded. RESULTS: A total of 30,805 patients were in the pulmonary TB and control cohorts. The incidence rate of HZ in pulmonary TB and control cohorts were 12.00 and 9.66 per 1000 person-years, respectively. The risk of HZ in the pulmonary TB cohort (adjusted hazard ratios = 1.23; 95% confidence interval = 1.16-1.30) was significantly higher than that of in control cohort. Among patients without comorbidities, the patients with TB were 1.28-fold more likely to have HZ than those without TB. CONCLUSION: Patients with TB should be well treated to avoid the potential risk of HZ occurrence. Although we identified the association between pulmonary TB and HZ, further studies are needed to confirm the result.


Subject(s)
Herpes Zoster , Mycobacterium tuberculosis , Tuberculosis, Pulmonary , Humans , Herpesvirus 3, Human , Cohort Studies , Herpes Zoster/epidemiology , Comorbidity , Tuberculosis, Pulmonary/epidemiology , Incidence , Risk Factors , Retrospective Studies
2.
Biomicrofluidics ; 16(6): 060401, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2186666
3.
Sustainability ; 13(15):8632, 2021.
Article in English | MDPI | ID: covidwho-1335208

ABSTRACT

The recent growth of learning technologies has catalyzed the surge in investments in e-learning systems across higher education to revolutionize pedagogical practices. Thus, the implementation of 3D virtual learning tools has become an indispensable, standard methodological tool in higher education. More recently, the enforcement of restrictions and emergency lockdowns to curb the spread of the COVID-19 pandemic compelled higher education institutions worldwide to cope with and meet the requirements of online education while preserving the quality of the learning experience at an equal pace. To develop a 3D physics laboratory, the appropriate equipment for physical experiments was first collected;then, the design software was applied to construct the 3D model. Software was then developed to edit the 3D experimental environment. Two practical tests were performed on the completed setup to verify the disadvantages and feasibility of the experiments. The present study develops and validates the incorporation of user satisfaction approaches to examine the quality of the most influential 3D learning tools during the coronavirus outbreak. The findings of this study confirm that 3D laboratories can positively influence learning attitudes when it comes to physics and improve learners’ understanding of physics concepts;they also confirm that 3D laboratories are a suitable tool for teaching physics experiments. Finally, the difficulties and solutions encountered in the development of the 3D laboratory are outlined as a reference for subsequent studies.

4.
Biomicrofluidics ; 14(6): 061502, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-975098

ABSTRACT

Infectious diseases caused by pathogens, such as SARS-COV, H7N9, severe fever with thrombocytopenia syndrome virus, and human immunodeficiency virus, have fatal outcomes with common features of severe fever and subsequent bacterial invasion progressing to multiorgan failure. Gene biomarkers are promising to distinguish specific infections from others with similar presenting symptoms for the prescription of correct therapeutics, preventing pandemics. While routine laboratory methods based on polymerase chain reaction (PCR) to measure gene biomarkers have provided highly sensitive and specific viral detection techniques over the years, they are still hampered by their precision and resource intensity precluding their point-of-care use. Recently, there has been growing interest in employing microfluidic technologies to advance current methods for infectious disease determination via gene biomarker measurements. Here, based on the requirement of infection detection, we will review three microfluidic approaches to compartmentalize gene biomarkers: (1) microwell-based PCR platforms; (2) droplet-based PCR; and (3) point-of-care devices including centrifugal chip, SlipChip, and self-powered integrated microfluidic point-of-care low-cost enabling chip. By capturing target genes in microwells with a small sample volume (∼µl), sensitivity can be enhanced. Additionally, with the advance of significant sample volume minimization (∼pl) using droplet technology, gene quantification is possible. These improvements in cost, automation, usability, and portability have thereby allowed point-of-care applications to decentralize testing platforms from laboratory-based settings to field use against infections.

SELECTION OF CITATIONS
SEARCH DETAIL